Monument Therapeutics is a UK-based clinical-stage biotech company focused on advancing precision medicine in the fields of psychiatry and neurology. The company utilizes digital biomarkers to identify biological differences among patients, which is crucial for enhancing the success rates of neuroscience drug development. By targeting patients with similar brain biology, Monument aims to improve the likelihood of effective responses to specific treatments. This approach mirrors the success seen in cancer drug approvals, where precision medicine has significantly increased the rate of successful outcomes.

The company's pipeline includes two primary treatment programs aimed at addressing cognitive impairment associated with schizophrenia and neuroinflammation. Monument Therapeutics leverages proprietary digital biomarkers to ensure precise patient selection, thereby enhancing the efficacy and safety of their novel formulations of well-characterized CNS-active small molecules. Their development strategy is designed for rapid progress, with a focus on generating early proof-of-concept data that can lead to Phase II clinical trials, ultimately aiming to meet significant unmet medical needs in central nervous system disorders.

United Kingdom

Monument Therapeutics is an independent UK based biotechnology company formed as a spin-out from Cambridge Cognition. The company is focused on bringing precision medicine to neuroscience drug development, with a pipeline of proprietary biomarkers that allows precise selection of patients most likely to benefit from treatment. Monument Therapeutics is de-risking development by repurposing drugs with a favorable safety profile and proven mechanisms.

Monument Therapeutics

Company Details